Get started
Work

Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques

Year: 2021
Type: article
Abstract: developed functional immunity in humans, with limited durability. Pfs230 conjugated to EPA (Pfs230D1-EPA) with liposomal adjuvant AS01 is currently in clinical trials in Mali. Studies with these conjugates revealed that non-human primates are better than mice to recapitulate the human immunogenicity and functional activity. Here, we evaluated the effect of ALFQ, a liposomal adjuvant consisting of TLR4 agonist and QS21, on the immunogenicity of Pfs25-EPA and Pfs230D1-EPA in Rhesus macaques. Both conjugates generated strong antibody responses and functional activity after two vaccinations though activity declined rapidly. A third vaccination of Pfs230D1-EPA induced functional activity lasting at least 9 months. Antibody avidity increased with each vaccination and correlated strongly with functional activity. IgG subclass analysis showed induction of Th1 and Th2 subclass antibody levels that correlated with activity.
Source: npj Vaccines
DOI: 10.1038/s41541-021-00407-3
Authors: Puthupparampil V. Scaria, Charles Anderson, Olga Muratova, Nada Alani, Hung V. Trinh, Steven T. Nadakal, Irfan Zaidi, Lynn Lambert, Zoltan Beck, Emma K. Barnafo, Kelly M. Rausch, Chris Rowe, Beth Chen, Gary R. Matyas, Mangala Rao, Carl R. Alving, David L. Narum, Patrick E. Duffy
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,170
Awards: ADDRESSING THE THREATS OF HIV AND EMERGING INFECTIOUS DISEASE TO THE MILITARY AND GLOBAL COMMUNITY THROUGH INNOVATIVE RESEARCH, G4119534169, G5850682332, G633733221, G7617460357, G8093122957, G8166743225
OpenAlex ID: W4200013221
FWCI: 3.954
Cites: 70
Cited by: 24
Related to: 10